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Abstract
Proteasome is a proteolytic complex responsible for intracellular protein turnover in eukary-
otes, archaea and in some actinobacteria species. Previous work has demonstrated that in
Schistosoma mansoni parasites, the proteasome inhibitor MG-132 affects parasite develop-
ment. However, the molecular targets affected by MG-132 in S. mansoni are not entirely
known. Here, we used expression microarrays to measure the genome-wide changes in
gene expression of S. mansoni adult worms exposed in vitro to MG-132, followed by in silico
functional analyses of the affected genes using Ingenuity Pathway Analysis (IPA). Scanning
electron microscopy was used to document changes in the parasites’ tegument. We identi-
fied 1,919 genes with a statistically significant (q-value 0.025) differential expression in
parasites treated for 24 h with MG-132, when compared with control. Of these, a total of
1,130 genes were up-regulated and 790 genes were down-regulated. A functional gene
interaction network comprised of MG-132 and its target genes, known from the literature to
be affected by the compound in humans, was identified here as affected by MG-132. While
MG-132 activated the expression of the 26S proteasome genes, it also decreased the ex-
pression of 19S chaperones assembly, 20S proteasome maturation, ubiquitin-like NEDD8
and its partner cullin-3 ubiquitin ligase genes. Interestingly, genes that encode proteins
related to potassium ion binding, integral membrane component, ATPase and potassium
channel activities were significantly down-regulated, whereas genes encoding proteins
related to actin binding and microtubule motor activity were significantly up-regulated. MG-
132 caused important changes in the worm tegument; peeling, outbreaks and swelling in
the tegument tubercles could be observed, which is consistent with interference on the ionic
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homeostasis in S. mansoni. Finally, we showed the down-regulation of Bax pro-apoptotic
gene, as well as up-regulation of two apoptosis inhibitor genes, IAP1 and BRE1, and in
contrast, down-regulation of Apaf-1 apoptotic activator, thus suggesting that apoptosis is
deregulated in S. mansoni exposed to MG-132. A considerable insight has been gained
concerning the potential of MG-132 as a gene expression modulator, and overall the data
suggest that the proteasome might be an important molecular target for the design of new
drugs against schistosomiasis.
Introduction
According to the World Health Organization, schistosomiasis is an acute and chronic parasitic
disease, which affects over 258 million individuals. The transmission has been documented in
78 countries, of which 52 are at higher risk [1,2]. Praziquantel (PZQ) is the only drug currently
recommended by WHO for preventive chemotherapy programs [3,4]. It is safe, mostly avail-
able, administered in one oral dose and inexpensive [4]. However, the existence of less suscep-
tible strains, reduced cure rate, and treatment failure after successive PZQ doses reinforce the
need for novel strategies of control of this parasitosis, based on safe and effective treatments
[5,6]. The identification and use of synthetic and biological inhibitors of the proteolytic activity
has mainly contributed to the characterization of essential functions of the 26S proteasome in
various processes and metabolic pathways in eukaryotic cells [7,8]. The effect of proteasome
inhibitors, such as MG-132 (Nα-benzyloxycarbonyl-l-leucyl-l-leucyl-leucinal), lactacystin and
other compounds, has been described in Entamoeba histolytica, Entamoeba invadens [9], Leish-
mania mexicana [10], Trypanosoma cruzi [11], T. brucei [12], Plasmodium berguei [13], Toxo-
plasma gondii [14] and Plasmodium falciparum [15,16], and for treatment of leishmaniasis,
Chagas disease and sleeping sickness [17]. Besides, proteasome inhibition has been described
as a promising tool to control a range of other diseases [18–21]. In 2005, Guerra-Sá et al. [22]
showed that MG-132 acted on the proteasome system and caused accumulation of high molec-
ular weight ubiquitinated proteins, also being able to reduce the number of lung stage schisto-
somula, the worm burden and consequently, the egg output in experimental schistosomiasis in
mice [22]. In schistosomiasis, eggs are the main cause of pathology, and the observed MG-132
effect of decreasing the egg output [22] argues for the importance of further characterizing the
molecular targets affected by MG-132 in S.mansoni.
The information generated through the genome and transcriptome projects opened up new
perspectives for understanding the parasite biology at the molecular level, in addition to the
identification of genes encoding proteins that might be promising candidates for vaccines and
potential targets for new drugs [23–29].
As a post-genomic tool, the microarray technology has produced large-scale transcriptional
data in Schistosoma [30–34]. These studies have provided lists of genes potentially involved in
the development and sexual differentiation of the parasite, which may contribute to a better
comprehension of these processes and identification of new pathways as targets for possible
therapeutic intervention [30–32,35–41]. More recently, the RNA-seq approach has contrib-
uted additional valuable information about the parasite transcriptome [38,42,43]. It is apparent
that genome-wide gene expression analyses should be useful to assess the impact of drugs like
MG-132 proteasome inhibitor on the parasite. In the current study, we investigated the effect
of MG-132 treatment on S.mansoni in vitro, using large-scale gene expression assays. The
present findings contribute to expand our knowledge about the parasite proteasome biology
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and to identify target molecules that might be important in the design of new drugs for preven-
tion and control of schistosomiasis.
Material and methods
Ethics statement
All procedures involving care and handling of animals were reviewed and approved by the
Ethical Committee for Animal Care of University of São Paulo (protocol number 021/2009),
in accordance with national (Brazilian legislation, CEUA, 11.794/2008) and international prin-
ciples for laboratory animal welfare. Six-week-old female BALB/c mice from the Animal
House of the University of São Paulo, Brazil, weighing 20±2.5 g, were used. The animals were
housed in groups of fifteen in wire-bottomed cages and maintained in a room with controlled
conditions (22 ± 2˚C, 55% humidity, and 12 h light/dark cycles), and food and filtered water
were provided ad libitum for 8 weeks. The cages were sanitized and animals were monitored
twice a week. The criteria used to assess animal health and well-being were the observation of
the behavior of the mice when opening a cage and the general physical state was evaluated by
observation of the color of the foot pads (anemia detection) and hydration by the eye and facial
fur appearance [44]. Mortality during the experiment period was not observed. S.mansoni
adult worms were recovered from the hepatic portal system and the liver of mice, 8 weeks after
infection, by perfusion under anesthesia with an intra-peritoneal injection of 40 mg/kg sodium
thiopental.
Chemicals
The proteasome inhibitor MG-132 (Nα-benzyloxycarbonyl-l-leucyl-l-leucyl-leucinal) was pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in DMSO.
In vitro treatment of S. mansoni with MG-132
The Luis Evangelista (LE) strain of S.mansoni was used. The life cycle of the parasite was rou-
tinely maintained by passage through Biomphalaria glabrata snails from a colony that was kept
at the animal house of the University of São Paulo. Cercariae shed from infected snails were
used for infecting BALB/c mice at the animal house (approximately 70 to 100 cercariae per ani-
mal) through the transcutaneous route [45]. S.mansoni adult worms were recovered from the
hepatic portal system and the liver of mice, 8 weeks after infection, by perfusion with citrate
saline (0.85% sodium chloride; 1.5% sodium citrate) that was pumped through a perfusing
needle placed in the left ventricle of the heart [45]; the perfusate and worms were collected
through the hepatic portal vein that was slit open [45]. These parasites were then incubated for
24 h (37˚C, 5% CO2) in RPMI 1640 medium (Invitrogen, Life Technologies Inc., Carlsbad,
CA, USA) supplemented with penicillin (100 UI/mL), streptomycin (100 μg/mL), and 10%
bovine fetal serum (Gibco, ThermoFisher Scientific Inc., Wilmington, DE, USA), containing
either 50 μM MG-132 (treated group) or 1% DMSO (vehicle, control group). This concentra-
tion of DMSO has been shown by our group [46] not to affect parasite mortality and parasite
motility, and by others [47] not to affect parasite worm morphology. It has been previously
observed that upon treatment of the parasites with 50 μM MG-132, there was no death of the
worms, however there was a decrease in oviposition in mice infected with treated parasites
[22]. Here, the colorimetric quantification test based on 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) [46] was used to monitor treated parasites viability.
Each adult worm couple was placed in a separate well of a 24-well plate, 50 μM MG-132
or vehicle was added and the couples were observed until they were separated; after 24 h,
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approximately 80% of couples had separated in the treatment assays and no separation was
observed in the controls. In the treatment assays, only separated couples were further used,
either for the viability test or for the measurement of gene expression with microarrays. For
the viability test, the MTT assay reagents were added to each couple 24 h after the addition of
MG-132 or vehicle, and six technical replicate couples were measured for each condition.
Three biological replicates were performed on different days, and the mean ± S.D. was calcu-
lated. For the microarray experiments, four biological replicates were obtained for each experi-
mental condition (treated or control). For each treatment replicate, 5 batches containing 20
separated worm pairs each were pooled. For the controls, the same number of paired couples
was used.
Total RNA isolation and microarray experiments
Total RNA was extracted from adult worms (treated and control groups) using Trizol reagent
(Invitrogen), according to the manufacturer’s protocol. The RNA samples were then treated
with DNAse I (QIAGEN, Hilden, Germany) and purified using Qiagen RNeasy mini kit (QIA-
GEN). The integrity of RNA samples was evaluated through microfluidic electrophoresis in
the Bioanalyzer equipment (Agilent Technologies, Santa Clara, CA, USA). RNA concentration
was measured in the NanoDropTM 1000 spectrophotometer (ThermoFisher Scientific Inc.,
Wilmington, DE, USA). Gene expression analysis was performed using the 4 x 44K oligoarray
platform, an oligonucleotide microarray slide containing 39,343 probes representing S.man-
soni gene fragments, designed by Verjovski-Almeida et al. [34], and manufactured by Agilent
Technologies. The platform probe annotation is available at the Gene Expression Omnibus
(GEO, https://www.ncbi.nlm.nih.gov/geo/) under the accession number GPL8606.
For each biological replicate, 500 ng of total RNA was amplified and fluorescently labeled
using Agilent Quick Amp Labeling Kit (Agilent Technologies), following the manufacturer’s
protocol for linear amplification and labeling of poly-A RNA by T7-RNA polymerase. For
each biological replicate a total of 825 ng Cy3- and Cy5-labeled cRNA from treated vs control
samples, respectively, was used for hybridization in each array. A second technical replicate
was obtained for each biological replicate, by labeling with opposite dyes, in a two-color dye-
swap approach. The slides were washed and processed according to the Two-Color Microar-
ray-Based Gene Expression Analysis (Quick Amp Labeling) Protocol (Agilent Technologies)
and scanned on a GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA, USA). Data
were extracted using Feature Extraction software (Agilent Technologies). Raw data is available
under accession number GSE57722 at GEO (https://www.ncbi.nlm.nih.gov/geo/).
Analysis of microarray data
Only genes with significantly detectable signal in at least 75% of all replicates in each group
(treated or control) were analyzed (using the IsPosAndSig column information from Feature
Extraction data output). The intensities were normalized by LOWESS algorithm [48], and the
log 2 ratios between treated and control groups were calculated. Pearson’s correlation coeffi-
cient (r) of signal intensity was used to evaluate biological and technical variability across the
samples. For the treated group: three biological replicates (r = 0.92, range = 0.85–0.97) and
technical replicate (r = 0.98, range = 0.97–0.99). For the control group: three biological repli-
cates (r = 0.94, range = 0.91–0.99) and technical replicate (r = 0.98, range = 0.97–0.99).
We used Significance Analysis of Microarray (SAM) [49] as the statistical test, to identify
differentially expressed genes using the log2 (treated/control) ratios. We performed SAM one-
class analyses and the genes were considered significantly differentially expressed at q-value
0.025. Hierarchical clustering of selected genes was generated using Spotfire Decision Site
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software (TIBCO Software Inc., Palo Alto, CA, USA). For a gene represented in the array by
multiple probes, we selected a single representative probe with the lowest coefficient of varia-
tion (obtained from intensity data of previous replicated experiments with the 44K
oligoarray).
Functional analyses of differentially expressed genes were performed using the Ingenuity
Pathway Analysis tool (IPA, QIAGEN Bioinformatics, QIAGEN, Redwood City, CA, USA).
For this purpose, we annotated S.mansoni genes encoding putative homologs to human pro-
teins; the putative homolog should have similarity with a BlastX e-value lower than 10−10 and
coverage of at least 60% of the human homolog. The RefSeq number of each human homolog
was associated to each S.mansoni gene and the expression data was uploaded to the IPA Sys-
tem version 7.6. We included all gene/protein relationships described in the IPA database as
experimentally observed and/or predicted with high confidence in the model animals, namely
human, mouse and rat.
Real-time quantitative PCR (q-PCR) validation of microarray data
One μg of DNAse-treated total RNA was reverse transcribed using the ThermoScriptRT-PCR
System (Invitrogen), in the presence of oligodT primer and Reverse Transcriptase, following
the manufacturer’s instructions. The resulting cDNA (0.5 μl) was used as template in the real-
time qPCR using SYBR green PCR Master Mix (Applied Biosystems, ThermoFisher Scientific
Inc., Wilmington, DE, USA), according to the manufacturer’s protocol. The qPCRs were run
in an ABI 7500 Real-Time PCR System (Applied Biosystems). The experiment was performed
with three independent biological replicates. Nuclease-free water was used as a non-template
control (NTC), and three technical replicates were run for each biological replicate. The rela-
tive levels of transcripts were calculated using the comparative ΔΔCt method, and α-tubulin
(GenBank accession M80214) was used as the endogenous control. Student t-test was used to
calculate the statistical significance between samples; the observed expression differences were
considered to be statistically significant at p< 0.05. Gene specific primers were designed using
the Primer3 software (http://primer3.sourceforge.net/) with default parameters (S1 Table).
Scanning electron microscopy
Tegument morphology of the parasites exposed to MG-132 treatment was investigated by
scanning electron microscopy. After exposing the parasites to 50 μM MG-132 or to vehicle
(control), the worms were rinsed in PBS (stabilized at 37˚C to prevent heat shock), fixed in 3%
glutaraldehyde for 60 min at 37˚C, incubated for 60 min at room temperature, washed twice
and maintained in PBS at 4˚C. The parasites were then post-fixed in 1% OsO4 in 100 mM
sodium phosphate buffer, pH 7.2, for 2 h at 4˚C. After post-fixing, the material was washed in
100 mM PBS three times, dehydrated in increasing concentrations of ethanol, and then main-
tained at the critical point (Critical Point Dryer 030, Bal-Tec, Balzers, Liechtenstein). Finally,
the dried specimens were mounted on aluminum stubs, and the material was visualized
through scanning electron microscopy using a JSM 6610LV electron microscope (JEOL Ltd.,
Tokyo, Japan) operated at 25 kV.
Results
Gene expression profile of S. mansoni adult worms treated with MG-132
We have previously observed that treatment of S.mansoni parasites with 50 μM MG-132
caused no death of the worms, however there was a decrease in oviposition in mice infected
with treated parasites [22]. Here we treated paired adult worm couples with 50 μM MG-132 or
Effects of MG-132 on Schistosoma mansoni
PLOS ONE | https://doi.org/10.1371/journal.pone.0184192 September 12, 2017 5 / 20
with vehicle and observed that after 24 h, approximately 80% of couples had separated in the
treatment assays and no separation was observed in the controls. For further assays, both the
viability test and the gene expression measurements, we only used the males and females that
had been separated upon treatment, and compared with paired couples from the controls. We
used the MTT colorimetric quantification test [46] to monitor treated parasites viability, and
found that upon treatment with MG-132 for 24 h there was a statistically significant 30%
decrease in the viability of separated adult worms, but no death of the parasites (S1 Fig).
Large-scale gene expression of MG-132-treated and control adult worm parasites was mea-
sured with custom-designed microarrays [34], and 10,056 out of 19,907 genes and gene frag-
ments probed on the arrays were detected as expressed (Table 1). Of these, a total of 1,919
genes exhibited a statistically significant (q-value 0.025) differential expression in S.mansoni
adult worms exposed for 24 h to MG-132 compared with controls (Fig 1). About 64% of the
differentially expressed genes, i.e. 1,231 genes are Smp-annotated genes predicted on the S.
mansoni genome, while the remaining 36% belong to other categories (Table 1).
Functional analysis of differentially expressed genes
To enhance our understanding of the molecular mechanisms by which S.mansoni responds to
the stress caused by MG-132, we performed functional analyses of the differentially expressed
genes using the the IPA tool. These functional analyses provide the biological context for gene
expression changes by integrating available literature information on model organisms
(human, mouse, rat) regarding molecular and chemical interactions, cellular phenotypes as
well as about signaling and metabolic pathways.
The IPA analysis revealed all interactions previously described in the literature between
MG-132 and the S.mansoni differentially expressed genes for which there are homologs in the
model organisms (S2 Fig). Among all 1,919 S.mansoni differentially expressed genes there are
376 genes that have homology to the human counterparts, out of which 287 were modeled by
IPA into a single network of interacting genes (S2 Fig) known in the literature to be primarily
or indirectly related with the effect of MG-132 in these model organisms.
Table 1. Number of genes with expression detected in each category generated by the analysis of microarray experiments.
Category Expressed
genes






(q-value <0.025) (q-value <0.025)
S. mansoni predicted genesa 3730 722 429 293
Anti-sense genes to S. mansoni
predicted genes
2604 510 298 212
S. mansoni homologs to S. japonicum
predicted genes
354 75 47 28
Anti-sense genes to S. japonicum
predicted genes
258 48 27 21
Homolog genes on GenBankb 858 159 95 64
Anti-sense genes to homolog genes on
GenBank
553 90 53 37
No match genes (with no homologs) 1,699 315 181 134
TOTAL 10,056 1,919 1,130 789
a S. mansoni Smp genes predicted in the parasite genome [23].
b Genes not predicted in the S. mansoni genome annotation, however annotated as having homologs in other species, using S. mansoni ESTs sequence
comparisons with BLASTp against the GenBank database of genes from all species [34].
https://doi.org/10.1371/journal.pone.0184192.t001
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As part of the above network, there were 17 genes or gene complexes whose expression was
affected by MG-132 in S.mansoni, for which the human homologs are described in the litera-
ture as primarily affected by the compound. These genes are highlighted in Fig 2, and the S2
Table gives the name of the corresponding S.mansoni homolog genes in this network and
summarizes the effect of MG-132 described in the literature.
Differentially expressed genes in adult worms treated with MG-132 are
involved in particularly interesting functions
We highlight a selection of 30 significantly (q 0.03) down-regulated genes (Fold
change< 0.73, or at least 1.3 X down-regulation) and 30 significantly (q 0.03) up-regulated
genes (Fold change > 1.3) with interesting biological functions in adult worms treated with
MG-132 compared with the control (Tables 2 and 3, respectively). These tables highlight the
molecules that may be involved in the disruption of parasite homeostasis. The genes are partic-
ularly interesting because they are involved in signal transduction processes, protein ubiquiti-
nation and degradation, and apoptosis, among other functions. Regarding apoptosis, Bax
gene, encoding a key pro-apoptotic protein, was down-regulated (Table 2), whereas Apoptotic
protease activating factor 1 (Apaf-1), encoding another pro-apoptotic protein, was up-regu-
lated (Table 3). S1 and S2 Datasets list all the 1,919 genes with repressed or induced expression,
respectively, in adult worms treated with MG-132.
Validation of microarray experiments by quantitative real-time PCR
Candidate genes were selected for real-time RT-PCR validation, based on their potential role
in the parasite biology and the hypothetical connection between the expression changes and
the phenotypical effects observed in the adult worms treated with MG-132, as we elaborate in
detail in the Discussion section further below. The selected genes are: NEDD8 (Smp_130170);
multidrug resistance protein 1, 2, 3 (Smp_170820); Bax regulator of apoptosis (Smp_095190);
POMP (Smp_074160); β subunit of DNA polymerase ε (Smp_124120); 26S proteasome
non-ATPase regulatory subunit (Smp_052870); subunit 4 activator of the 26S proteasome
(Smp_126760); S3 regulatory subunit of the 26S proteasome (Smp_085310.2) and the bicoid
protein interaction (Smp_021750.2). Alpha-tubulin was used as reference gene. Fig 3 shows
that all selected genes were validated; Fig 3 also shows the results of the comparison between
the data obtained by microarray and real-time RT-PCR. The consistency between microarray
and real time RT-PCR data was verified through Pearson’s correlation (r = 0.98).
Scanning electron microscopy
Parasite tegument was observed through scanning electron microscopy in order to document
the damage caused by exposure to 50 μM MG-132 (Fig 4). The analyses were performed in the
posterior region of the parasite. Fig 4A to 4D show a normal tegument in S.mansoni adult
worms in the control group, which is rich in well-organized tubercles with many spines ran-
domly distributed throughout the body. These tubercles are surrounded by spines. Fig 4E to
Fig 1. Effect of MG-132 on gene expression profile in Schistosoma mansoni adult worms. Adult worm
pairs were treated for 24 h with 50 μM MG-132. Microarrays were used to measure gene expression on a
large scale. The figure shows a group of 1,919 genes with a statistically significant (q-value 0.025)
differential expression in adult worms treated with MG-132 versus controls. Each horizontal line represents a
gene and each column represents an experimental replicate. There are two technical replicates for each one
of four biological replicates. Genes with transcription induced by treatment are shown in red, genes with
repressed transcription are in green, and the color intensity is proportional to the log2 ratio (treated/control), as
indicated by the color scale at the bottom.
https://doi.org/10.1371/journal.pone.0184192.g001
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Fig 2. Highlighted gene interaction network between MG-132 and S. mansoni differentially expressed genes
whose homologs in model organisms are described in the literature as being affected by the compound. Each
line represents a direct (filled line) or an indirect (dashed line) relationship between the gene products. Yellow lines
highlight the interactions between compound MG-132 and the affected gene products according to the literature; blue
lines indicate the interactions among the differentially expressed genes. An arrowhead indicates a change in expression,
activation or localization of the gene product, and an arrow line with a broken end indicates an inhibitory relationship.
Each symbol shape represents a different gene category, as indicated in the symbol shapes legend at the bottom of the
figure. Gene names are given inside the symbols, and the corresponding Smp gene annotation for each S. mansoni
gene is given in S2 Table. Red color indicates that the expression of the indicated gene was up-regulated, and green
indicates that the expression was down-regulated in S. mansoni adult worms treated with MG-132 compared with the
control. This interaction network was obtained with the Ingenuity Pathway Analysis (IPA) tool as previously described
[50,51], and the analysis is further detailed in the Methods. At the top of the figure, genes belonging to the canonical
pathway (CP) called “Protein Ubiquitination Pathway” are pointed with black lines.
https://doi.org/10.1371/journal.pone.0184192.g002
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4H show changes in the tegument caused by the exposure to MG-132. Upon treatment with
MG-132, peeling (p) was observed. Additionally, it was possible to identify outbreaks (o) and
swelling (s) in the tubercles.
Discussion
Proteasomes are major sites for ubiquitin-targeted protein degradation in eukaryotic cells
[52,53] and play fundamental roles in the development of diverse parasites [10,13–17,22]. In S.
mansoni, MG-132 proteasome inhibitor has been shown by our group to cause a marked accu-
mulation of high-molecular weight ubiquitinated proteins, as detected by immunoblotting
with anti-ubiquitin antibodies, thus evidencing the on target-engagement of the worm protea-
some by MG-132 [22]. In the current study, we measured the large-scale gene expression
changes induced in adult worms upon treatment with MG-132, in an attempt to document the
molecular events that underlie the phenotypical changes previously reported by Guerra-Sá
et al. [22], such as the separation of adult worm pairs and interruption of female oviposition
caused by MG-132.
Table 2. Representative list of 30 repressed genes in S. mansoni adult worms in response to MG-132 treatment.
ProbeName Contig Gene Smp Gene annotation Fold Change
Q2_P08728 C902198.1 Smp_171620 methylthioadenosine phosphorylase, putative 0.17
Q2_P32288 C908635.1 Smp_087230 5-formyltetrahydrofolate cyclo-ligase, putative 0.17
Q2_P17855 C921267.1 Smp_120510 steroid dehydrogenase, putative 0.18
Q2_P21581 C805071.1 Smp_002160 DNA methyltransferase 1 associated protein 1 [Homo sapiens] 0.2
Q2_P40316 JAP03944.S Smp_095190 apoptosis regulator bax, putative 0.23
Q2_P13201 C910061.1 Smp_137460 cytoplasmic polyadenylation element binding protein (cpeb), putative 0.24
Q2_P22707 C806602.1 - smooth muscle myosin heavy chain 11 isoform SM2A [Homo sapiens] 0.24
Q2_P38626 JAP09001.C - tumor protein p63 regulated 1-like [Homo sapiens] 0.26
Q2_P09722 C903654.1 Smp_159440 schwannomin interacting protein, putative 0.27
Q2_P11632 C906993.1 Smp_135770 zinc finger protein, putative 0.27
Q2_P37788 C919228.1 Smp_158480 AMP dependent ligase, putative 0.27
Q2_P21035 C804288.1 - glutathione peroxidase 7 [Homo sapiens] 0.27
Q2_P05882 C810644.1 Smp_046430 ubiquitin-specific peptidase 42 (C19 family) 0.29
Q2_P30711 C905469.1 Smp_105360 Notch 0.29
Q2_P38356 C921416.1 Smp_130170 ubiquitin 1, putative; NEDD8 [Homo sapiens] 0.45
Q2_P35165 C914173.1 Smp_020170 voltage-dependent calcium channel 0.49
Q2_P08644 C902082.1 Smp_181150 ABC transporter, putative 0.52
Q2_P01145 C802678.1 Smp_100390 cullin 3 [Homo sapiens] 0.53
Q2_P07889 C900200.1 Smp_158460 breast cancer anti-estrogen resistance 1 [Homo sapiens] 0.55
Q2_P36177 C915996.1 Smp_043360 nudix-type motif 6 isoform a [Homo sapiens] 0.56
Q2_P36268 C916112.1 Smp_170820 multidrug resistance protein 1, 2, 3, putative 0.57
Q2_P27355 C813427.1 Smp_074160 proteasome maturation protein [Homo sapiens] 0.58
Q2_P31182 C906514.1 Smp_004730 voltage-dependent calcium channel 0.62
Q2_P08701 C902158.1 Smp_020270 voltage-dependent calcium channel 0.63
Q2_P08404 C901707.1 Smp_056440 superoxide dismutase [mn], putative 0.66
Q2_P22162 C805866.1 Smp_049600.x DNAj (hsp40) homolog, subfamily C, member, putative 0.67
Q2_P22815 C806740.1 Smp_156150 calcium-activated potassium channel 0.67
Q2_P16841 C917848.1 Smp_064380 aspartate aminotrasferase, putative 0.72
Q2_P32712 C909486.1 Smp_003190 26S proteasome subunit P28-related 0.72
Q2_P21772 C805348.1 Smp_168480 apoptosis inhibitor, putative 0.73
https://doi.org/10.1371/journal.pone.0184192.t002
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When the information about the effect of MG-132 available at the IPA tool database was
associated with all S.mansoni differentially expressed genes (that have human gene homologs),
a network was constructed (S2 Fig) and we identified genes (highlighted in Fig 2) that, accord-
ing to the literature, are affected by MG-132 (changes in expression level, protein activity or
localization). It suggests that there are conserved responses related to the ubiquitin-protea-
some system in the parasite and in model animals such as humans, mice and rats. In this
respect, it should be noted that MG-132 is a well-documented inhibitor of cysteine proteases
(cathepsins and calpain) as well as of the proteasome multicatalytic protease [54] in diverse
animals. In P. falciparum for example, MG-132 is a dual-target inhibitor, inhibiting both cyste-
ine proteases and the ubiquitin proteasomal system [55]. We cannot rule out the possibility
that these alternate protease targets may influence some of the expression changes detected
here.
While many reports in the literature have investigated the role of the proteasome complex
in S.mansoni biology and phenotype [22,56–58], here we assessed for the first time the large-
scale differential expression of proteasome genes caused by a proteasome inhibitor; curiously,
most of these genes were up-regulated under MG-132 treatment. Thus, we observed the
Table 3. Representative list of 30 induced genes in S. mansoni adult worms in response to MG-132 treatment.
ProbeName Contig Gene Smp Gene annotation Fold Change
Q2_P08423 C901740.1 Smp_121780 serine/threonine kinase 1.32
Q2_P37907 C919420.1 Smp_085310.2 26S proteasome regulatory subunit S3, putative 1.40
Q2_P37636 C918731.1 Smp_067890 proteasome subunit alpha 2 (T01 family) 1.49
Q2_P05423 C810048.1 Smp_140260 apoptotic peptidase activating factor 1 isoform b [Homo sapiens] 1.53
Q2_P40330 JAP04182.S - proteasome 26S non-ATPase subunit 5 [Homo sapiens] 1.56
Q2_P36517 C916741.1 Smp_017070 26S protease regulatory subunit S10b, putative 1.59
Q2_P24543 C809045.1 Smp_042150 Dynein light chain 1. cytoplasmic, putative 1.68
Q2_P25077 C809737.1 Smp_052870 26S proteasome non-ATPase regulatory subunit, putative 1.83
Q2_P13768 C911179.1 Smp_122680 oligophrenin, putative 1.90
Q2_P30182 C904635.1 Smp_123620 C85 protease (C85 family) 2.63
Q2_P20759 C803931.1 Smp_076740 30S ribosomal protein S8, putative 2.70
Q2_P27440 C900096.1 Smp_126760 proteasome (prosome, macropain) activator subunit 4 [Homo sapiens] 2.71
Q2_P21612 C805121.1 Smp_021750.2 bicoid-interacting protein related 3.60
Q2_P29186 C903263.1 Smp_131070 condensin, putative 4.28
Q2_P02684 C805352.1 - asp (abnormal spindle)-like, microcephaly associated [Homo sapiens] 4.78
Q2_P01813 C803891.1 Smp_061310.3 chromosome 15 open reading frame 24 [Homo sapiens] 4.83
Q2_P33526 C910959.1 Smp_150140 PI3kinase, putative 4.94
Q2_P23192 C807248.1 Smp_124120 DNA polymerase epsilon subunit b, putative 4.95
Q2_P14061 C911711.1 Smp_139810 Ubiquitin-protein ligase BRE1, putative 5.17
Q2_P28151 C901770.1 Smp_141580 protein kinase 5.42
Q2_P13391 C910365.1 Smp_143920 integrator complex subunit 9 isoform 1 [Homo sapiens] 6.03
Q2_P12516 C908685.1 Smp_045470 homeobox protein prospero/prox-1/ceh-26. putative 6.18
Q2_P29138 C903195.1 Smp_129470 dystroglycan 1 preproprotein [Homo sapiens] 6.22
Q2_P01162 C802712.1 - discoidin domain receptor family, member 2 precursor [Homo sapiens] 7.33
Q2_P12459 C908573.1 Smp_160830 phospholipase d–related 8.01
Q2_P12817 C909349.1 Smp_097620 vacuolar protein sorting 25 [Homo sapiens] 8.41
Q2_P37055 C917660.1 Smp_164620 cortactin, putative 9.95
Q2_P00261 C800825.1 Smp_065190.2 thioredoxin-like protein, putative 10.8
Q2_P12610 C908920.1 Smp_130590 inhibitor of apoptosis 1, diap1, putative 11.2
Q2_P01503 C803351.1 - jumonji domain containing 1B [Homo sapiens] 19.5
https://doi.org/10.1371/journal.pone.0184192.t003
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induction of genes encoding catalytic and regulatory particles (α1, α2 and Rpt4) and protea-
some activator subunit 4 (an activator PA200 subunit), which might participate in regulation
of the proteolytic activity [59]. Our data also showed increased gene expression of 26S protea-
some non-ATPase regulatory subunit 5 (S5) (Smp_125800 homologue to Sjp_0022550), which
Fig 3. Microarray results validation by real-time PCR. Validation is shown for a group of selected differentially expressed genes in S. mansoni adult
worms treated with MG-132 compared with control parasites. Real time PCR data, expressed as Fold Change (normalized to the control group) are
displayed as a bar graph while the corresponding data from the microarray (fold change) are shown below in numbers. The asterisk (*) indicates a
statistically significant change (p < 0.05, t-test) when comparing treated with control samples.
https://doi.org/10.1371/journal.pone.0184192.g003
Fig 4. Scanning electron microscopy of the tegument of S. mansoni adult worms. (A, x600) Normal morphology of adult worm tegument. (B, x1200)
and (C, x3000) magnification of normal morphology of S. mansoni tegument showing the large number of tubercles (tu) and spines (sp). (D, x5000)
Magnification of normal morphology of S. mansoni tegument showing spines (sp). (E, x600) Morphology of S. mansoni tegument after treatment with 50 μM
MG-132 for 24 h. (F, x1200) Magnification showing tegumental changes in treated male adult worms: peeling (p), swelling (s), outbreak (o). (G, x3000) and (H,
x5000) Magnification showing peeling (p) and bubbles (b) in the tegument promoted by MG-132.
https://doi.org/10.1371/journal.pone.0184192.g004
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is encoded by the PSMD5 gene [60] and has been identified as a functional homolog of the
chaperone Hsm3 in mammals [61]. In this way, our data suggest that under the inhibition
caused by MG-132, treated parasites are engaged in the recovery of the proteasome function
through the synthesis of new proteasome units. Similarly, De Paula et al. [62] showed that dif-
ferent types of stress could drastically up-regulate the expression of two proteasome genes,
namely SmHul5 and SmUbp6, suggesting that the proteasome is important in the cellular
stress response in this parasite.
In contrast to the up-regulation of most proteasome genes, we found down-regulation of
two chaperone homologs, which are involved with proteasome regulatory particle (RP) base
assembly [63], namely chaperone homologs Hsm3 and Nas6, as well as down-regulation of the
homolog of the proteasome maturation protein (POMP) gene (Smp_074160), which is among
the most highly down-regulated genes (Table 2). In yeast, the POMP gene, also known as
Ump1, plays a fundamental role in maturation of the 20S proteasome catalytic core [64,65] and
deletion of Ump1 results in accentuated decrease of 26S proteasome catalytic core [66].
Therefore, the present results indicate that while proteasome inhibition by MG-132 acti-
vates the expression of genes encoding subunits of the 26S proteasome, it also decreases the
expression of genes encoding important 19S chaperones assembly and 20S proteasome matu-
ration protein. These results suggest that the proteolytic activity of the proteasome fails to get
recovered, as shown by the accumulation in the parasite of high molecular weight ubiquiti-
nated proteins [22], thus possibly resulting in cellular damage and a decreased viability of the
parasites. Repression of NEDD8 (Smp_130170) expression, observed here in the presence of
MG-132 (Fig 2), might add to the factors contributing to the loss of parasite viability. NEDD8
encodes an ubiquitin-like protein that plays an important role in cell cycle progression, growth
and survival, thus regulating cell growth, viability and development [67]. Attachment of
NEDD8 to cullins activates their associated E3 ubiquitin ligase activity, and thus promotes
polyubiquitination and proteasomal degradation of cyclins and other regulatory proteins [68].
Besides NEDD8 down-regulation, we observed a significant down-regulation of cullin 3
(Smp_100390) (Table 2), the gene encoding a partner of NEDD8 which appears as an impor-
tant gene hub in the network of MG-132 affected genes (S2 Fig), thus reinforcing the hypothe-
sis that the proteolytic activity of the proteasome is considerably reduced.
We observed among the down-regulated genes (Table 2), an important number of genes
encoding ion channels such as: high voltage-activated calcium channel Cav1 (Smp_020270,
Smp_020170 and Smp_004730), calcium-activated potassium channel (Smp_156150) and
hyperpolarization activated cyclic nucleotide-gated potassium channel (Smp_153100). The ion
channels are pore-forming membrane proteins and protein complexes that underlie electrical
excitability and fast neurotransmission, as well as other rapidly-changing biological functions
in cells [69]. The decreased expression of these transcripts observed here could explain the pre-
viously detected separation of adult worm pairs induced by MG-132 [22], since changes in the
membrane potential and ionic homeostasis imbalance might result in impaired muscular con-
traction in these parasites. Also, tegument damage observed here might be associated with
changes in transcript levels of ion channels.
In addition, we observed down-regulation of genes encoding multidrug resistance (MDR)
proteins such as ABCB1 (Smp_170820) (Table 2 and Fig 2), ABC transporter (Smp_181150)
(Table 2) and copper ABC transporter (Smp_144970) (S1 Dataset). These transporters are
responsible for the detoxification of xenobiotics, metal ions and metabolic toxins. Noteworthy,
praziquantel has an opposite effect, namely an increased expression of these transporters
[35,70] and a reduced sensitivity to praziquantel correlates with higher levels of MDR trans-
porters [70]. Interestingly, genetic knockdown and pharmacological inhibition of the MDR
transporters disrupts egg production by S.mansoni [71]. The reduced expression of MDR
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genes caused by MG-132 might contribute to the sensitivity of the parasite to the drug, and be
related to the previously observed MG-132-induced drastic inhibition of egg production of S.
mansoni adult worms [22]. In this respect, the observed marked down-regulation of CPEB
gene (Smp_137460) with MG-132 seems relevant (Table 2); in Xenopus, CPEB controls the
oocytes germ cells development [72,73], suggesting that germ cells development and cell divi-
sion, essential to oogenesis, could be inhibited and impaired by the decrease in CPEB expres-
sion caused by MG-132 in S.mansoni. Further direct characterization of oocytes function in
the female parasite is required. In addition, it is noteworthy that the present results were
obtained with the pool of adult male and female worms and we expect that they will open new
perspectives to explore the gender specific effects of MG-132 in future studies.
Intriguingly, while one gene encoding a pro-apoptotic protein, Apoptotic protease activat-
ing factor 1 (Apaf-1) (Smp_140260) was up-regulated, a number of homolog genes in the apo-
ptotic pathway were affected in the opposite direction, suggesting a possible diminished
apoptosis. Thus, Bax (Smp_095190) encoding a key pro-apoptotic protein was among the top
down-regulated genes in S.mansoni exposed to MG-132 (Table 2), while two genes contribut-
ing to apoptosis inhibition were among the top up-regulated (Table 3). One is the gene encod-
ing the inhibitor of apoptosis protein 1 (IAP1) (Smp_130590), which was one of the most
highly induced genes in the treated parasites (11-fold up-regulated) (Table 3). Molecular char-
acterization of the inhibitor of apoptosis in Schistosoma japonicum (SjIAP) has shown that its
transcription occurs predominantly at the developmental stages present in the mammalian
final host [74]. The second up-regulated gene (Smp_139810) encodes the ubiquitin ligase
BRE1 (Table 3); this protein exhibits an anti-apoptotic activity in Sacharomyces cerevisiae, and
an increased level of Bre1p in S. cerevisiae has an evident role in protecting from hydrogen per-
oxide-induced cell death, whereas its deletion enhances cell death [75]. Our results suggest
that up-regulation of BRE1 in S.mansoni, as a result of MG-132 treatment, may contribute to
dampen the activation of the cell death processes.
Presence of the mitochondrial Bcl-2-regulated apoptosis pathway in Schistosoma [76]
makes this pathway evolutionarily close to that of humans and Caenorhabditis elegans. In
mammalian cells, Bcl-2 family proteins such as Bax are central regulators of apoptosis, which
is a process essential for cellular homeostasis, life development, and prevention of pathological
conditions [77]. Together, our results suggest a deregulated apoptosis pathway due to a
decreased expression of its key-activating component Bax, and an increased expression of apo-
ptosis inhibitors IAP1 and BRE1. This result is in contrast to the induction pattern seen in
mammalian tumor cells treated with MG-132 [78,79] where an increased apoptosis [78] and
an increased expression of genes such as p38 kinase and JNK1 [79] have been observed. In
fact, in line with the opposite effect of MG-132 on the parasite compared with tumor cells, the
S.mansoni p38 kinase (Smp_133020) and JNK1 (Smp_172240) gene homologs were detected
here as expressed, however not significantly affected by MG-132, thus reinforcing the finding
that apoptosis might not be induced, but rather diminished in the treated parasite. This might
not be surprising, because in tumor cells, treatment with proteasome inhibitors prevents NF-
κB activation and leads to toxic accumulation of misfolded proteins, which in turn activates
JNK1 and apoptosis [80], whereas S.mansoni does not have an NF-κB homolog. Overall,
deregulation of the apoptosis pathway caused by MG-132 might compromise S.mansoni cell
homeostasis, and consequently decrease parasite viability.
Conclusions
The proteasome inhibition in S.mansoni led to changes in expression of genes involved in cel-
lular processes other than protein degradation, which documents that the proteasome is
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essential for gene expression regulation, and suggests that the proteasome might be an impor-
tant molecular target for the design of new drugs against this parasite.
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